FR2848554A1 - Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant - Google Patents
Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant Download PDFInfo
- Publication number
- FR2848554A1 FR2848554A1 FR0215720A FR0215720A FR2848554A1 FR 2848554 A1 FR2848554 A1 FR 2848554A1 FR 0215720 A FR0215720 A FR 0215720A FR 0215720 A FR0215720 A FR 0215720A FR 2848554 A1 FR2848554 A1 FR 2848554A1
- Authority
- FR
- France
- Prior art keywords
- phenyl
- indazol
- chloro
- fluoro
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004770 neurodegeneration Effects 0.000 title claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 title claims description 7
- 206010028980 Neoplasm Diseases 0.000 title claims description 6
- 208000008589 Obesity Diseases 0.000 title claims description 6
- 235000020824 obesity Nutrition 0.000 title claims description 6
- 201000010065 polycystic ovary syndrome Diseases 0.000 title claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 5
- 208000030159 metabolic disease Diseases 0.000 title claims description 5
- YDTDKKULPWTHRV-UHFFFAOYSA-N 1H-indazol-3-amine Chemical class C1=CC=C2C(N)=NNC2=C1 YDTDKKULPWTHRV-UHFFFAOYSA-N 0.000 title abstract description 14
- 229940043355 kinase inhibitor Drugs 0.000 title description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 3
- 206010036049 Polycystic ovaries Diseases 0.000 title description 2
- 206010020772 Hypertension Diseases 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 166
- -1 trifluoromethyl sulfanyl Chemical group 0.000 claims abstract description 163
- 125000003118 aryl group Chemical group 0.000 claims abstract description 133
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 127
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 93
- 150000002367 halogens Chemical class 0.000 claims abstract description 92
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 81
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract description 68
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims abstract description 63
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 57
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 51
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 51
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims abstract description 48
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 37
- 125000005592 polycycloalkyl group Polymers 0.000 claims abstract description 34
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 33
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims abstract description 32
- 150000003839 salts Chemical class 0.000 claims abstract description 32
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract description 23
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 12
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 claims abstract description 10
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims abstract description 9
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- LCUAIJVCGLCVRV-UHFFFAOYSA-N 1-[6,7-difluoro-5-phenyl-1-(2-trimethylsilylethoxymethyl)indazol-3-yl]-3-phenylurea Chemical compound C12=CC(C=3C=CC=CC=3)=C(F)C(F)=C2N(COCC[Si](C)(C)C)N=C1NC(=O)NC1=CC=CC=C1 LCUAIJVCGLCVRV-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000000543 intermediate Substances 0.000 claims abstract 2
- QYUOATCXTVZREV-UHFFFAOYSA-N n-[5-bromo-6,7-difluoro-1-(2-trimethylsilylethoxymethyl)indazol-3-yl]butanamide Chemical compound FC1=C(Br)C=C2C(NC(=O)CCC)=NN(COCC[Si](C)(C)C)C2=C1F QYUOATCXTVZREV-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000001424 substituent group Chemical group 0.000 claims description 49
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 47
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 45
- 150000003254 radicals Chemical class 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 8
- 239000004202 carbamide Substances 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- 125000005469 ethylenyl group Chemical group 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 5
- 208000007530 Essential hypertension Diseases 0.000 claims description 5
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 208000027232 peripheral nervous system disease Diseases 0.000 claims description 5
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 102000013498 tau Proteins Human genes 0.000 claims description 3
- 108010026424 tau Proteins Proteins 0.000 claims description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 2
- PTZQAROLQHBISX-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-(1h-pyrrol-2-ylmethyl)-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC1=CC=CN1 PTZQAROLQHBISX-UHFFFAOYSA-N 0.000 claims description 2
- NPAZRALOOWPTLV-UHFFFAOYSA-N 6-chloro-7-fluoro-n-(2,2,3,3,4,4,4-heptafluorobutyl)-5-phenyl-1h-indazol-3-amine Chemical compound C=1C=2C(NCC(F)(F)C(F)(F)C(F)(F)F)=NNC=2C(F)=C(Cl)C=1C1=CC=CC=C1 NPAZRALOOWPTLV-UHFFFAOYSA-N 0.000 claims description 2
- NPHGEMPKWGRKIH-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCC1=CC(=CC=C1)OC)C1=CC=CC=C1.ClC1=CC=C(C=C1)CNC1=NNC2=C(C(=C(C=C12)C1=CC=CC=C1)Cl)F Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCC1=CC(=CC=C1)OC)C1=CC=CC=C1.ClC1=CC=C(C=C1)CNC1=NNC2=C(C(=C(C=C12)C1=CC=CC=C1)Cl)F NPHGEMPKWGRKIH-UHFFFAOYSA-N 0.000 claims description 2
- USQJHRQPECCCAK-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCC1=CC=C(C=C1)C#N)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1=CC=CC=C1)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCC1=CC=C(C=C1)C#N)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1=CC=CC=C1)C1=CC=CC=C1 USQJHRQPECCCAK-UHFFFAOYSA-N 0.000 claims description 2
- IQLBGPPCLGRLJC-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCCN1CCOCC1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCCN1CCCCC1)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCCN1CCOCC1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCCN1CCCCC1)C1=CC=CC=C1 IQLBGPPCLGRLJC-UHFFFAOYSA-N 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims description 2
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims description 2
- UKYWIKNIISMJTR-UHFFFAOYSA-N n-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-4-(trifluoromethyl)benzenesulfonamide Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 UKYWIKNIISMJTR-UHFFFAOYSA-N 0.000 claims description 2
- VZFLJAVTYDHVSF-UHFFFAOYSA-N n-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12 VZFLJAVTYDHVSF-UHFFFAOYSA-N 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 2
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 claims 1
- OWNDTEWCMBFNEN-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=N[C]=CN1 OWNDTEWCMBFNEN-UHFFFAOYSA-N 0.000 claims 1
- ZCUSNQPYUNLATP-UHFFFAOYSA-N 5-phenyl-1h-indazol-3-amine Chemical compound C1=C2C(N)=NNC2=CC=C1C1=CC=CC=C1 ZCUSNQPYUNLATP-UHFFFAOYSA-N 0.000 claims 1
- JSGISZCYCLUJLZ-UHFFFAOYSA-N 6,7-difluoro-5-phenyl-1-(2-trimethylsilylethoxymethyl)indazol-3-amine N-[6,7-difluoro-5-phenyl-1-(2-trimethylsilylethoxymethyl)indazol-3-yl]butanamide Chemical compound FC1=C(C=C2C(=NN(C2=C1F)COCC[Si](C)(C)C)N)C1=CC=CC=C1.C(CCC)(=O)NC1=NN(C2=C(C(=C(C=C12)C1=CC=CC=C1)F)F)COCC[Si](C)(C)C JSGISZCYCLUJLZ-UHFFFAOYSA-N 0.000 claims 1
- UUJFJKOLVDOAKC-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-(2,4,6-trifluorophenyl)-1h-indazol-3-amine Chemical compound FC1=CC(F)=CC(F)=C1NC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12 UUJFJKOLVDOAKC-UHFFFAOYSA-N 0.000 claims 1
- FCERHBBRLXWHHW-UHFFFAOYSA-N 6-chloro-7-fluoro-n-(3-nitrophenyl)-5-phenyl-1h-indazol-3-amine;6-chloro-7-fluoro-n-(4-nitrophenyl)-5-phenyl-1h-indazol-3-amine Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12.[O-][N+](=O)C1=CC=CC(NC=2C3=CC(=C(Cl)C(F)=C3NN=2)C=2C=CC=CC=2)=C1 FCERHBBRLXWHHW-UHFFFAOYSA-N 0.000 claims 1
- PAHCXFWKWFTIKL-UHFFFAOYSA-N 6-chloro-n-(cyclopropylmethyl)-7-fluoro-5-phenyl-1h-indazol-3-amine;6-chloro-7-fluoro-5-phenyl-n-(3-phenylpropyl)-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC1CC1.N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCCCC1=CC=CC=C1 PAHCXFWKWFTIKL-UHFFFAOYSA-N 0.000 claims 1
- AIODXUQWCFPTSO-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NC1=CC=CC=C1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC=C(C=C1)OC)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC(=CC=C1)OC)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NC1=CC=CC=C1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC=C(C=C1)OC)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC(=CC=C1)OC)C1=CC=CC=C1 AIODXUQWCFPTSO-UHFFFAOYSA-N 0.000 claims 1
- CYZGPRHIDPNKLW-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCC1=CC(=CC=C1)OC1=CC=C(C=C1)C)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1=CC=C(C=C1)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCC1=CC(=CC=C1)OC1=CC=C(C=C1)C)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1=CC=C(C=C1)F)C1=CC=CC=C1 CYZGPRHIDPNKLW-UHFFFAOYSA-N 0.000 claims 1
- MFSGZHBYWIJBTQ-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCCC)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1CCCCC1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCCC1=CC=CC=C1)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCCC)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1CCCCC1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCCC1=CC=CC=C1)C1=CC=CC=C1 MFSGZHBYWIJBTQ-UHFFFAOYSA-N 0.000 claims 1
- OALIUNOOWANTHI-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCCCSC)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1CCCC1)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCCCSC)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1CCCC1)C1=CC=CC=C1 OALIUNOOWANTHI-UHFFFAOYSA-N 0.000 claims 1
- 229940089960 chloroacetate Drugs 0.000 claims 1
- 208000013044 corticobasal degeneration disease Diseases 0.000 claims 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-M ethanimidate Chemical compound CC([O-])=N DLFVBJFMPXGRIB-UHFFFAOYSA-M 0.000 claims 1
- GISQYVRSLBHUMJ-UHFFFAOYSA-N n-(5-bicyclo[2.2.1]hept-2-enylmethyl)-6-chloro-7-fluoro-5-phenyl-1h-indazol-3-amine Chemical compound C=1C=2C(NCC3C4CC(C=C4)C3)=NNC=2C(F)=C(Cl)C=1C1=CC=CC=C1 GISQYVRSLBHUMJ-UHFFFAOYSA-N 0.000 claims 1
- YGSWUAZYNANWJD-UHFFFAOYSA-N n-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-1-methylimidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NC=2C3=CC(=C(Cl)C(F)=C3NN=2)C=2C=CC=CC=2)=C1 YGSWUAZYNANWJD-UHFFFAOYSA-N 0.000 claims 1
- YPKFLCNLGPOPCN-UHFFFAOYSA-N n-butyl-6-chloro-7-fluoro-5-phenyl-1h-indazol-3-amine Chemical compound C1=C2C(NCCCC)=NNC2=C(F)C(Cl)=C1C1=CC=CC=C1 YPKFLCNLGPOPCN-UHFFFAOYSA-N 0.000 claims 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract description 6
- PEIFULAAYQSODW-UHFFFAOYSA-N n-(6,7-difluoro-1h-indazol-3-yl)butanamide Chemical compound FC1=CC=C2C(NC(=O)CCC)=NNC2=C1F PEIFULAAYQSODW-UHFFFAOYSA-N 0.000 abstract description 4
- SVCNLECORJCINH-UHFFFAOYSA-N 6,7-difluoro-1h-indazol-3-amine Chemical compound FC1=CC=C2C(N)=NNC2=C1F SVCNLECORJCINH-UHFFFAOYSA-N 0.000 abstract description 3
- HLAUZGMPWBIZCZ-UHFFFAOYSA-N 6,7-difluoro-5-phenyl-1-(2-trimethylsilylethoxymethyl)indazol-3-amine Chemical compound FC=1C(F)=C2N(COCC[Si](C)(C)C)N=C(N)C2=CC=1C1=CC=CC=C1 HLAUZGMPWBIZCZ-UHFFFAOYSA-N 0.000 abstract description 3
- LXRBHYUNGXVGLB-UHFFFAOYSA-N n-[6,7-difluoro-5-phenyl-1-(2-trimethylsilylethoxymethyl)indazol-3-yl]butanamide Chemical compound C1=C2C(NC(=O)CCC)=NN(COCC[Si](C)(C)C)C2=C(F)C(F)=C1C1=CC=CC=C1 LXRBHYUNGXVGLB-UHFFFAOYSA-N 0.000 abstract description 3
- XWVSKNXUROZXMZ-UHFFFAOYSA-N n-[6,7-difluoro-1-(2-trimethylsilylethoxymethyl)indazol-3-yl]butanamide Chemical compound FC1=CC=C2C(NC(=O)CCC)=NN(COCC[Si](C)(C)C)C2=C1F XWVSKNXUROZXMZ-UHFFFAOYSA-N 0.000 abstract description 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- 229910052757 nitrogen Chemical group 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 229910052763 palladium Inorganic materials 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000012429 reaction media Substances 0.000 description 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
- 125000004404 heteroalkyl group Chemical group 0.000 description 4
- 230000007813 immunodeficiency Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 0 *CCCc(c(cc1)c2c(*)c1Cl)n[n]2-c1ccccc1 Chemical compound *CCCc(c(cc1)c2c(*)c1Cl)n[n]2-c1ccccc1 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- NOTFZGFABLVTIG-UHFFFAOYSA-N Cyclohexylethyl acetate Chemical compound CC(=O)OCCC1CCCCC1 NOTFZGFABLVTIG-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 235000013877 carbamide Nutrition 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- CPRRHERYRRXBRZ-SRVKXCTJSA-N methyl n-[(2s)-1-[[(2s)-1-hydroxy-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)C[C@@H]1CCNC1=O CPRRHERYRRXBRZ-SRVKXCTJSA-N 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 2
- NERBTAODYFWYER-UHFFFAOYSA-N 1-(6,7-difluoro-5-phenyl-1h-indazol-3-yl)-3-phenylurea Chemical compound C1=2C=C(C=3C=CC=CC=3)C(F)=C(F)C=2NN=C1NC(=O)NC1=CC=CC=C1 NERBTAODYFWYER-UHFFFAOYSA-N 0.000 description 2
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- YYLLIJHXUHJATK-UHFFFAOYSA-N Cyclohexyl acetate Chemical compound CC(=O)OC1CCCCC1 YYLLIJHXUHJATK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000005840 aryl radicals Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000001119 stannous chloride Substances 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- XIUJWWJXLQJGGW-UHFFFAOYSA-N (6-chloro-7-methyl-5-phenyl-1h-indazol-3-yl)urea Chemical compound C=1C=2C(NC(N)=O)=NNC=2C(C)=C(Cl)C=1C1=CC=CC=C1 XIUJWWJXLQJGGW-UHFFFAOYSA-N 0.000 description 1
- 102100027831 14-3-3 protein theta Human genes 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- GDHXJNRAJRCGMX-UHFFFAOYSA-N 2-fluorobenzonitrile Chemical compound FC1=CC=CC=C1C#N GDHXJNRAJRCGMX-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- SADVHEXWFHVSGZ-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-[[3-(trifluoromethyl)phenyl]methyl]-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC1=CC=CC(C(F)(F)F)=C1 SADVHEXWFHVSGZ-UHFFFAOYSA-N 0.000 description 1
- FZAZWOKCOXATOA-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-[[4-(trifluoromethoxy)phenyl]methyl]-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC1=CC=C(OC(F)(F)F)C=C1 FZAZWOKCOXATOA-UHFFFAOYSA-N 0.000 description 1
- NBQAORFEWFDVIT-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-[[4-(trifluoromethyl)phenyl]methyl]-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC1=CC=C(C(F)(F)F)C=C1 NBQAORFEWFDVIT-UHFFFAOYSA-N 0.000 description 1
- CUJZDDCQVTWLDE-UHFFFAOYSA-N 6-chloro-n-(3,3-dimethylbutyl)-7-fluoro-5-phenyl-1h-indazol-3-amine;6-chloro-7-fluoro-5-phenyl-n-(3-phenylpropyl)-1h-indazol-3-amine Chemical compound C1=C2C(NCCC(C)(C)C)=NNC2=C(F)C(Cl)=C1C1=CC=CC=C1.N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCCCC1=CC=CC=C1 CUJZDDCQVTWLDE-UHFFFAOYSA-N 0.000 description 1
- HJEJCJKHALBUSL-UHFFFAOYSA-N 6-chloro-n-(cyclohexylmethyl)-7-fluoro-5-phenyl-1h-indazol-3-amine;6-chloro-7-fluoro-5-phenyl-n-propyl-1h-indazol-3-amine Chemical compound C1=C2C(NCCC)=NNC2=C(F)C(Cl)=C1C1=CC=CC=C1.N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC1CCCCC1 HJEJCJKHALBUSL-UHFFFAOYSA-N 0.000 description 1
- IXSFRRMIUBJQNY-UHFFFAOYSA-N 6-chloro-n-[[4-(dimethylamino)phenyl]methyl]-7-fluoro-5-phenyl-1h-indazol-3-amine Chemical compound C1=CC(N(C)C)=CC=C1CNC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12 IXSFRRMIUBJQNY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ATSSJQHXLKKOCJ-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NC1=CC(=C(C=C1)F)F)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=C(C(=C(C(=C1F)F)F)F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NC1=CC(=C(C=C1)F)F)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=C(C(=C(C(=C1F)F)F)F)F)C1=CC=CC=C1 ATSSJQHXLKKOCJ-UHFFFAOYSA-N 0.000 description 1
- CKOOCXZEFYEKMM-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NC1=CC(=CC=C1)OC)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC(=CC=C1)[N+](=O)[O-])C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NC1=CC(=CC=C1)OC)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC(=CC=C1)[N+](=O)[O-])C1=CC=CC=C1 CKOOCXZEFYEKMM-UHFFFAOYSA-N 0.000 description 1
- JEARJOOYHLHESV-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC=C1 JEARJOOYHLHESV-UHFFFAOYSA-N 0.000 description 1
- KXVNPJWIJCPZRM-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NC1=CC=C(C=C1)F)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=C(C=C(C=C1F)F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NC1=CC=C(C=C1)F)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=C(C=C(C=C1F)F)F)C1=CC=CC=C1 KXVNPJWIJCPZRM-UHFFFAOYSA-N 0.000 description 1
- GLDNUYKOHWPIGI-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NC1=CC=C(C=C1)[N+](=O)[O-])C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC(=CC(=C1)C(F)(F)F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NC1=CC=C(C=C1)[N+](=O)[O-])C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC(=CC(=C1)C(F)(F)F)F)C1=CC=CC=C1 GLDNUYKOHWPIGI-UHFFFAOYSA-N 0.000 description 1
- RPMUUNQOSPAKRW-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCC1=CC=C(C=C1)OC)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCCCC(F)(F)F)C1=CC=CC=C1.O Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCC1=CC=C(C=C1)OC)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCCCC(F)(F)F)C1=CC=CC=C1.O RPMUUNQOSPAKRW-UHFFFAOYSA-N 0.000 description 1
- BONJXORHECMVIQ-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCC1CCCC1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1CC1)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCC1CCCC1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1CC1)C1=CC=CC=C1 BONJXORHECMVIQ-UHFFFAOYSA-N 0.000 description 1
- BJSHMUUGLPJWFZ-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCC=1N=C(NC1)C)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1=NNC=C1)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCC=1N=C(NC1)C)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1=NNC=C1)C1=CC=CC=C1 BJSHMUUGLPJWFZ-UHFFFAOYSA-N 0.000 description 1
- RULVROHSLZOZEB-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCC=1N=C(NC1)C1=CC=CC=C1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC=1C(=NN(C1C)C1=CC=CC=C1)C)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCC=1N=C(NC1)C1=CC=CC=C1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC=1C(=NN(C1C)C1=CC=CC=C1)C)C1=CC=CC=C1 RULVROHSLZOZEB-UHFFFAOYSA-N 0.000 description 1
- KTTBXRSLXDAJDZ-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCCC1=CC=CC=C1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCCCSC)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCCC1=CC=CC=C1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCCCSC)C1=CC=CC=C1 KTTBXRSLXDAJDZ-UHFFFAOYSA-N 0.000 description 1
- XTOHJCIZETZHOA-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NN1CC=CC=C1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC=CC=C1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC=C(C=C1)OC)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NN1CC=CC=C1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC=CC=C1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC=C(C=C1)OC)C1=CC=CC=C1 XTOHJCIZETZHOA-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 101150057615 Syn gene Proteins 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 150000001638 boron Chemical class 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007336 electrophilic substitution reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- KAFDJFDAFKULGY-UHFFFAOYSA-N ethyl 2-[[(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)amino]methyl]-4-methylsulfanyl-1h-imidazole-5-carboxylate Chemical compound N1C(SC)=C(C(=O)OCC)N=C1CNC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12 KAFDJFDAFKULGY-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004245 indazol-3-yl group Chemical group [H]N1N=C(*)C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- AAIJVOLZAKVXGB-UHFFFAOYSA-N n-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-4-methoxybenzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12 AAIJVOLZAKVXGB-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- QSABSXVSSUNPOJ-UHFFFAOYSA-N n-[4-[[(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)amino]methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12 QSABSXVSSUNPOJ-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000005593 norbornanyl group Chemical group 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- ABOYDMHGKWRPFD-UHFFFAOYSA-N phenylmethanesulfonamide Chemical compound NS(=O)(=O)CC1=CC=CC=C1 ABOYDMHGKWRPFD-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- USISRUCGEISZIB-UHFFFAOYSA-N piperidin-3-one Chemical compound O=C1CCCNC1 USISRUCGEISZIB-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- QGKLPGKXAVVPOJ-UHFFFAOYSA-N pyrrolidin-3-one Chemical compound O=C1CCNC1 QGKLPGKXAVVPOJ-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- ALZJERAWTOKHNO-UHFFFAOYSA-M sodium;dodecyl sulfate;3-morpholin-4-ylpropane-1-sulfonic acid Chemical compound [Na+].OS(=O)(=O)CCCN1CCOCC1.CCCCCCCCCCCCOS([O-])(=O)=O ALZJERAWTOKHNO-UHFFFAOYSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (30)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0215720A FR2848554A1 (fr) | 2002-12-12 | 2002-12-12 | Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant |
| PE2003000886A PE20040996A1 (es) | 2002-12-12 | 2003-09-01 | Derivados de aminoindazol como inhibidores de quinasas, procesos para su preparacion y composiciones farmaceuticas que los contienen |
| PE2009001071A PE20091629A1 (es) | 2002-12-12 | 2003-09-01 | Derivados de aminoindazol como inhibidores de quinasas, procesos para su preparacion y composiciones farmaceuticas que los contienen |
| EP03769560A EP1572200B1 (fr) | 2002-12-12 | 2003-09-03 | Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases |
| CNA038256169A CN1713909A (zh) | 2002-12-12 | 2003-09-03 | 氨基吲唑衍生物及其作为激酶抑制剂的用途 |
| CA002507948A CA2507948A1 (fr) | 2002-12-12 | 2003-09-03 | Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases |
| AT03769560T ATE520399T1 (de) | 2002-12-12 | 2003-09-03 | Aminoindazole derivate als kinase inhibitoren |
| MXPA05005554A MXPA05005554A (es) | 2002-12-12 | 2003-09-03 | Derivados de aminoindazol y su utilizacion como inhibidores de quinasas. |
| CN2010105043043A CN101979382A (zh) | 2002-12-12 | 2003-09-03 | 氨基吲唑衍生物及其作为激酶抑制剂的用途 |
| KR1020057010709A KR20050084271A (ko) | 2002-12-12 | 2003-09-03 | 아미노인다졸 유도체 및 키나제 억제제로서의 이의 용도 |
| PL376789A PL376789A1 (pl) | 2002-12-12 | 2003-09-03 | Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy |
| RU2005121897/04A RU2339624C2 (ru) | 2002-12-12 | 2003-09-03 | Производные аминоиндазолов и их применение в качестве ингибиторов киназ |
| HR20050533A HRP20050533A2 (en) | 2002-12-12 | 2003-09-03 | Aminoindazole derivatives and use thereof as kinase inhibitors |
| MEP-253/08A MEP25308A (en) | 2002-12-12 | 2003-09-03 | Aminoindazole derivatives and use thereof as kinase inhibitors |
| ARP030103187A AR041132A1 (es) | 2002-12-12 | 2003-09-03 | Derivados de aminoindazol utilizados como medicamentos y composiciones farmaceuticas que los contienen |
| AU2003278250A AU2003278250B2 (en) | 2002-12-12 | 2003-09-03 | Aminoindazole derivatives and use thereof as kinase inhibitors |
| YUP-2005/0421A RS20050421A (sr) | 2002-12-12 | 2003-09-03 | Derivati aminoindazola i njihova upotreba kao inhibitora kinaza |
| NZ541193A NZ541193A (en) | 2002-12-12 | 2003-09-03 | Aminoindazole derivatives and use thereof as kinase inhibitors |
| JP2005512867A JP4764168B2 (ja) | 2002-12-12 | 2003-09-03 | アミノインダゾール誘導体及びキナーゼ阻害剤としてのその使用 |
| BR0316606-6A BR0316606A (pt) | 2002-12-12 | 2003-09-03 | Derivados de aminoindazóis e sua utilização como inibidores de quinases |
| PCT/FR2003/002634 WO2004062662A1 (fr) | 2002-12-12 | 2003-09-03 | Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases |
| US10/654,698 US7019011B2 (en) | 2002-12-12 | 2003-09-04 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them |
| TW092124409A TWI345561B (en) | 2002-12-12 | 2003-09-04 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them |
| MYPI20033346A MY138085A (en) | 2002-12-12 | 2003-09-04 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them |
| ZA200504681A ZA200504681B (en) | 2002-12-12 | 2005-06-08 | Aminoindazole derivatives and use thereof as kinase inhibitors |
| MA28328A MA27561A1 (fr) | 2002-12-12 | 2005-06-10 | Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases |
| NO20053356A NO330835B1 (no) | 2002-12-12 | 2005-07-11 | Aminindazolderivater, fremgangsmate for fremstilling derav, mellomprodukt samt farmasoytisk preparat inneholdende et slikt derivat |
| US11/285,874 US7196109B2 (en) | 2002-12-12 | 2005-11-23 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them |
| US11/683,452 US7407981B2 (en) | 2002-12-12 | 2007-03-08 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them |
| US12/143,070 US7629374B2 (en) | 2002-12-12 | 2008-06-20 | Use of aminoindazole derivatives for the inhibition of tau phosphorylation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0215720A FR2848554A1 (fr) | 2002-12-12 | 2002-12-12 | Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR2848554A1 true FR2848554A1 (fr) | 2004-06-18 |
Family
ID=32338720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR0215720A Pending FR2848554A1 (fr) | 2002-12-12 | 2002-12-12 | Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant |
Country Status (11)
| Country | Link |
|---|---|
| JP (1) | JP4764168B2 (https=) |
| CN (2) | CN1713909A (https=) |
| AR (1) | AR041132A1 (https=) |
| AT (1) | ATE520399T1 (https=) |
| FR (1) | FR2848554A1 (https=) |
| ME (1) | MEP25308A (https=) |
| MY (1) | MY138085A (https=) |
| PE (2) | PE20040996A1 (https=) |
| RS (1) | RS20050421A (https=) |
| TW (1) | TWI345561B (https=) |
| ZA (1) | ZA200504681B (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008086854A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | 5-([1,3,4] 0xadiaz0l-2-yl)-1h-indazol und 5-([1,3,4] thiadiaz0l-2-yl)-1h-indazol derivate als sgk-inhibitoren zur behandlung von diabetes |
| DE102007022565A1 (de) | 2007-05-14 | 2008-11-20 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2439773T3 (es) * | 2009-02-26 | 2014-01-24 | Glaxo Group Limited | Derivados de pirazol usados como antagonistas del receptor CCR4 |
| CA2989519C (en) | 2015-06-15 | 2023-09-26 | Ube Industries, Ltd. | Substituted dihydropyrrolopyrazole derivative |
| CN115260165B (zh) * | 2021-04-29 | 2024-08-06 | 中国科学院上海药物研究所 | 苯并含氮五元杂环化合物及其合成和应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002022601A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2003028720A1 (en) * | 2001-09-26 | 2003-04-10 | Pharmacia Italia S.P.A. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51143010A (en) * | 1975-06-04 | 1976-12-09 | Kao Corp | Stable bleaching detergent composition |
| US6593349B2 (en) * | 2001-03-19 | 2003-07-15 | Icagen, Inc. | Bisarylamines as potassium channel openers |
| FR2836915B1 (fr) * | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
| BR0314098A (pt) * | 2002-09-05 | 2005-07-19 | Aventis Pharma Sa | Derivados da aminoindazóis a tìtulo de medicamentos e composições farmacêuticas que os contêm |
-
2002
- 2002-12-12 FR FR0215720A patent/FR2848554A1/fr active Pending
-
2003
- 2003-09-01 PE PE2003000886A patent/PE20040996A1/es not_active Application Discontinuation
- 2003-09-01 PE PE2009001071A patent/PE20091629A1/es not_active Application Discontinuation
- 2003-09-03 AR ARP030103187A patent/AR041132A1/es unknown
- 2003-09-03 CN CNA038256169A patent/CN1713909A/zh active Pending
- 2003-09-03 JP JP2005512867A patent/JP4764168B2/ja not_active Expired - Fee Related
- 2003-09-03 CN CN2010105043043A patent/CN101979382A/zh active Pending
- 2003-09-03 ME MEP-253/08A patent/MEP25308A/xx unknown
- 2003-09-03 RS YUP-2005/0421A patent/RS20050421A/sr unknown
- 2003-09-03 AT AT03769560T patent/ATE520399T1/de not_active IP Right Cessation
- 2003-09-04 TW TW092124409A patent/TWI345561B/zh not_active IP Right Cessation
- 2003-09-04 MY MYPI20033346A patent/MY138085A/en unknown
-
2005
- 2005-06-08 ZA ZA200504681A patent/ZA200504681B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002022601A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2003028720A1 (en) * | 2001-09-26 | 2003-04-10 | Pharmacia Italia S.P.A. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008086854A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | 5-([1,3,4] 0xadiaz0l-2-yl)-1h-indazol und 5-([1,3,4] thiadiaz0l-2-yl)-1h-indazol derivate als sgk-inhibitoren zur behandlung von diabetes |
| DE102007002717A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
| DE102007022565A1 (de) | 2007-05-14 | 2008-11-20 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
Also Published As
| Publication number | Publication date |
|---|---|
| PE20040996A1 (es) | 2005-01-28 |
| CN1713909A (zh) | 2005-12-28 |
| TWI345561B (en) | 2011-07-21 |
| TW200422293A (en) | 2004-11-01 |
| JP2006516266A (ja) | 2006-06-29 |
| RS20050421A (sr) | 2007-08-03 |
| AR041132A1 (es) | 2005-05-04 |
| JP4764168B2 (ja) | 2011-08-31 |
| PE20091629A1 (es) | 2009-11-16 |
| ATE520399T1 (de) | 2011-09-15 |
| CN101979382A (zh) | 2011-02-23 |
| MY138085A (en) | 2009-04-30 |
| MEP25308A (en) | 2010-06-10 |
| ZA200504681B (en) | 2006-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1572200B1 (fr) | Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases | |
| EP1537087B1 (fr) | Derives de 3-aminoindazole comme inhibiteurs de kinase et compositions pharmaceutiques les renfermant | |
| EP1487804B1 (fr) | Derives d'aminoindazoles comme inhibiteurs de proteine-kinase | |
| FR2847253A1 (fr) | Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant | |
| OA12222A (fr) | Compositions pharmaceutiques contenant des dérivésd'azetidine, les nouveaux dérivés d'azetidine et leur préparation. | |
| WO2003020314A1 (fr) | Compositions pour le traitement de la maladie de parkinson contenant un antagoniste du recepteur cb1 et un produit qui active la neurotransmission dopaminergique dans le cerveau | |
| FR2848554A1 (fr) | Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant | |
| FR2844267A1 (fr) | Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant | |
| FR2812546A1 (fr) | Derives d'heterocycles a 5 chainons, leur preparation et leur application a titre de medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RN | Application for restoration | ||
| IC | Decision of the director general to declare irreceivable or to reject an appeal |